Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and ...

Foresight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the ...

In this video, Arvind Dasari, MD, MS, discussed data from multiple ASCO Gastrointestinal Cancers Symposium presentations highlighting the use of ctDNA as a minimal residual disease in colorectal ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive minimal residual disease, or MRD, detection, recently expanded its ...

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...

Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...

Allogene Therapeutics expands collaboration with Foresight Diagnostics to advance development activities in Europe, UK, Canada & Australia: South San Francisco, California Thursda ...

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...